1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Global Clinical Trials Review, H2, 2015

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Global Clinical Trials Review, H2, 2015" provides an overview of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) clinical trials scenario. This report provides top line data relating to the clinical trials on Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials 28
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 135
Abbreviations 135
Definitions 135
Research Methodology 136
Secondary Research 136
About GlobalData 137
Contact Us 137
Disclaimer 137
Source 138

List of Tables
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials by Region, 2015* 7
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, North America, Top Countries, 2015* 12
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14
Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials, G7 Countries (%), 2015* 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials, E7 Countries (%), 2015* 18
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials by Phase, 2015* 21
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 26
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29

List of Figures
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials by Region (%), 2015* 7
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14
Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials, G7 Countries (%), 2015* 15
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17
Proportion of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) to Hematological Disorders Clinical Trials, E7 Countries (%), 2015* 18
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 25
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 26
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 27
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 28
Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 29
GlobalData Methodology 136

Companies Mentioned
GlaxoSmithKline Plc
Amgen Inc.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Rigel Pharmaceuticals, Inc.
Baxter International Inc.
Protalex, Inc.
C. H. Boehringer Sohn AG and Co. KG
Biogen, Inc.
AstraZeneca Plc

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.